184 related articles for article (PubMed ID: 34565560)
1. Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma.
Emmons MF; Smalley KSM
J Invest Dermatol; 2022 Jan; 142(1):18-20. PubMed ID: 34565560
[TBL] [Abstract][Full Text] [Related]
2. CAMKK2 Defines Ferroptosis Sensitivity of Melanoma Cells by Regulating AMPK‒NRF2 Pathway.
Wang S; Yi X; Wu Z; Guo S; Dai W; Wang H; Shi Q; Zeng K; Guo W; Li C
J Invest Dermatol; 2022 Jan; 142(1):189-200.e8. PubMed ID: 34242660
[TBL] [Abstract][Full Text] [Related]
3. Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of Melanoma.
Wang S; Guo Q; Xu R; Lin P; Deng G; Xia X
J Nanobiotechnology; 2023 Oct; 21(1):383. PubMed ID: 37858186
[TBL] [Abstract][Full Text] [Related]
4. A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy.
Del Rosso M; Fibbi G; Laurenzana A; Margheri F; Chillà A
J Invest Dermatol; 2021 Nov; 141(11):2566-2568. PubMed ID: 34688409
[TBL] [Abstract][Full Text] [Related]
5. Targeting ferroptosis as a cell death pathway in Melanoma: From molecular mechanisms to skin cancer treatment.
Manzari Tavakoli G; Mirzapour MH; Razi S; Rezaei N
Int Immunopharmacol; 2023 Jun; 119():110215. PubMed ID: 37094541
[TBL] [Abstract][Full Text] [Related]
6. CD8
Wang W; Green M; Choi JE; Gijón M; Kennedy PD; Johnson JK; Liao P; Lang X; Kryczek I; Sell A; Xia H; Zhou J; Li G; Li J; Li W; Wei S; Vatan L; Zhang H; Szeliga W; Gu W; Liu R; Lawrence TS; Lamb C; Tanno Y; Cieslik M; Stone E; Georgiou G; Chan TA; Chinnaiyan A; Zou W
Nature; 2019 May; 569(7755):270-274. PubMed ID: 31043744
[TBL] [Abstract][Full Text] [Related]
7. BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition.
Meng Y; Sun HY; He Y; Zhou Q; Liu YH; Su H; Yin MZ; Zeng FR; Chen X; Deng GT
Mil Med Res; 2023 Dec; 10(1):61. PubMed ID: 38049916
[No Abstract] [Full Text] [Related]
8. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
Eggermont AM; Maio M; Robert C
Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
[TBL] [Abstract][Full Text] [Related]
9. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11.
Lang X; Green MD; Wang W; Yu J; Choi JE; Jiang L; Liao P; Zhou J; Zhang Q; Dow A; Saripalli AL; Kryczek I; Wei S; Szeliga W; Vatan L; Stone EM; Georgiou G; Cieslik M; Wahl DR; Morgan MA; Chinnaiyan AM; Lawrence TS; Zou W
Cancer Discov; 2019 Dec; 9(12):1673-1685. PubMed ID: 31554642
[TBL] [Abstract][Full Text] [Related]
11. Could SIRPA expression predict response to anti-PD-1 immunotherapy?
Jogerst K; Boland G
Cancer Cell; 2022 Nov; 40(11):1269-1270. PubMed ID: 36332626
[TBL] [Abstract][Full Text] [Related]
12. A Physiological Function for Ferroptosis in Tumor Suppression by the Immune System.
Stockwell BR; Jiang X
Cell Metab; 2019 Jul; 30(1):14-15. PubMed ID: 31269423
[TBL] [Abstract][Full Text] [Related]
13. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
15. Gambogenic acid induces ferroptosis in melanoma cells undergoing epithelial-to-mesenchymal transition.
Wang M; Li S; Wang Y; Cheng H; Su J; Li Q
Toxicol Appl Pharmacol; 2020 Aug; 401():115110. PubMed ID: 32533954
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
18. Firing up the cold tumors by targeting Vps34.
Janji B; Hasmim M; Parpal S; Berchem G; Noman MZ
Oncoimmunology; 2020 Aug; 9(1):1809936. PubMed ID: 32939326
[TBL] [Abstract][Full Text] [Related]
19. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
20. Novel Targets for the Treatment of Melanoma.
Ambrosi L; Khan S; Carvajal RD; Yang J
Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
